Publications by authors named "Justin D Lutz"

Claim this Profile
C
Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.
Donghong Xu, Justin D Lutz, Punag Divanji, Jianlin Li, Youcef Benattia

Clin Pharmacokinet· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.
Donghong Xu, Justin D Lutz, Punag Divanji, Jianlin Li, Youcef Benattia

Clin Pharmacokinet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Caroline J Coats, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Michael Arad, Justin D Lutz

J Am Heart Assoc· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
Maribel Reyes, Justin D Lutz, Audrey H Lau, Anuj Gaggar, Ethan P Grant

Antivir Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat.
Brian J Kirby, Justin D Lutz, Mun Sang Yue, Kimberly L Garrison, Ann Ran-Ran Qin

Clin Pharmacol Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
Rita Humeniuk, Anita Mathias, Brian J Kirby, Justin D Lutz, Huyen Cao

Clin Pharmacokinet· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
Justin D Lutz, Anita Mathias, Polina German, Cheryl Pikora, Sunila Reddy

Clin Pharmacol Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications.
Maciej J Zamek-Gliszczynski, Mitesh Patel, Xinning Yang, Justin D Lutz, Xiaoyan Chu

Clin Pharmacol Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Albert Liclican, Loredana Serafini, Weimei Xing, Gregg Czerwieniec, Bart Steiner, Justin D Lutz

Biochim Biophys Acta Gen Subj· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine.
Justin D Lutz, Brian J Kirby, Lu Wang, Qinghua Song, John Ling

Clin Pharmacol Ther· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin.
Justin D Lutz, Brian J Kirby, Lu Wang, Qinghua Song, John Ling

Clin Pharmacol Ther· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator.
Daphne Williams, Xiaolu Tao, Lili Zhu, Michele Stonier, Justin D Lutz

Br J Clin Pharmacol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct protein-protein interactions and substrate channeling between cellular retinoic acid binding proteins and CYP26B1.
Cara H Nelson, Chi-Chi Peng, Justin D Lutz, Catherine K Yeung, Alex Zelter

FEBS Lett· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.
Jessica Tay-Sontheimer, Laura M Shireman, Richard P Beyer, Taurence Senn, Daniela Witten, Justin D Lutz

Pharmacogenomics· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
Kayode K Ojo, Richard T Eastman, Ramasubbarao Vidadala, Zhongsheng Zhang, Kasey L Rivas, Justin D Lutz

J Infect Dis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
Justin D Lutz, Brooke M VandenBrink, Katipudi N Babu, Wendel L Nelson, Kent L Kunze

Drug Metab Dispos· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.
Yoshiyuki Shirasaka, Jennifer E Sager, Justin D Lutz, Connie Davis, Nina Isoherranen

Drug Metab Dispos· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.
Nina Isoherranen, Justin D Lutz, Sophie P Chung, Houda Hachad, Rene H Levy

Chem Res Toxicol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.
Justin D Lutz, Nina Isoherranen

Expert Opin Drug Metab Toxicol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.
Chi-Chi Peng, Wei Shi, Justin D Lutz, Kent L Kunze, Jun O Liu

Drug Metab Dispos· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.
Justin D Lutz, Nina Isoherranen

Drug Metab Dispos· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases.
Ariel R Topletz, Jayne E Thatcher, Alex Zelter, Justin D Lutz, Suzanne Tay

Biochem Pharmacol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.
Justin D Lutz, Yasushi Fujioka, Nina Isoherranen

Expert Opin Drug Metab Toxicol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.
Justin D Lutz, Vaishali Dixit, Catherine K Yeung, Leslie J Dickmann, Alex Zelter

Biochem Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis